Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs

G. Rachelefsky, C. Paramore, N. K. Leidy (Los Angeles, Bethesda, United States Of America)

Source: Annual Congress 2001 - Leukotriene receptor antagonists in clinical practice
Session: Leukotriene receptor antagonists in clinical practice
Session type: Thematic Poster Session
Number: 1777
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Rachelefsky, C. Paramore, N. K. Leidy (Los Angeles, Bethesda, United States Of America). Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs. Eur Respir J 2001; 16: Suppl. 31, 1777

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice
Source: Annual Congress 2010 - Management of airway disease
Year: 2010


Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007


The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006



Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 8s
Year: 2002

Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

The effects of addition montelukast to inhaled steroids in the regular treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma
Source: Annual Congress 2009 - Epidemiology of atopy and asthma
Year: 2009

Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Low-dose inhaled glucocorticoids are more effective tham LTRA in improving functional data in asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004